|
|
Lung/Chest Studies Currently Recruiting Participants at the Simmons Cancer Research Center at Southern Illinois University School of Medicine
| Protocol Title |
Study # |
Study Group |
| A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 CM) Peripheral Non-Small Cell Lung Cancer |
CALGB 140503 |
SIU Thoracic |
| Brachytherapy Following Sublobar Resection in High Risk Patients With Stage I Non-Small Cell Lung Carcinoma |
I 125 |
SIU Thoracic |
| Adjuvant Non-Small Cell Lung Cancer |
| A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation |
ECOG E6508 |
CICCOP |
| A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4cm)-IIIA Non-Small Lung Cancer (NSCLC) |
ECOG E1505 |
CICCOP |
Locally Advanced & Metastatic |
| Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer |
CTSU-CALGB 30607 |
CICCOP |
| Antigen Specific Cancer Immunotherapeutic (ASCI) study |
GSK MAGE- A-3 |
SIU Thoracic |
| A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) Selected by Serum Proteomics |
SWOG S0709 |
CICCOP |
| A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) |
SWOG S0819 |
CICCOP |
|
Bronchioalveolar Cancer (BAC)
|
| Small Cell |
| Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
CTSU-CALGB 30610 |
CICCOP |
| A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) |
SWOG S0802 |
CICCOP |
|
Mesothelioma, 2nd Line |
| Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) |
SWOG S0722 |
CICCOP |
| Cancer Control |
| Compare the Outcomes of Four Groups of Lung cancer Patients Who Consent to Participate |
Behavior Outcomes Trial |
SIU Thoracic |
Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.
Contact Information:
Simmons Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823
- Kathy Robinson, PhD,
Director of Clinical Trials
(217) 545-1946
-
Allicent Curry, RN,BSN, OCN
Research Nurse
(217) 545-7929 -
-
-
-
-
SIU Behavioral & Psychosocial Oncology
- Anna Wiggins, MS, LCPC
(217) 545-5408
-
SIU COG
- Carol Peterson, RN, CCRP (217) 545-7377
SIU IM
- Amanda Fogleman, B.S. (217) 545-0592
- Krista Whitlock (217) 545-7750
SIU Thoracic
- Theresa Boley, RN, MSN, APN/FNP-BC, CCRP (217) 545-5000
-
- Cathy Leslie, RN, CCRP (217) 545-8184
- Mary Ray, MS (217) 545-7420
-
RTOG: Radiation Therapy Oncology Group:
- Diana Weyhenmeyer, RN, MA, OCN (217) 544-6464 ext. 45591
CICCOP: Central Illinois Community Clinical Oncology Program
Memorial Medical Center CICCOP Research Contacts:
Treatment/Cancer Control:
- Holly Thomas (217) 788-4178
- Stephanie Allbritton (217) 788-3544
- Brooke Trickey (217) 217-788-3560
- Karen Graber (217) 588-2961
- Chrissy Tucker (217) 788-4444
Sunny Hampsey (217) 788-4233
Back to Open Clinical Trials
|
 |
|
